Tumor necrosis factor (TNF) in inflammatory bowel disease: Gene polymorphisms, animal models, and potential for anti-TNF therapy

Journal of Inflammation

Volumn 47, Issue 1-2, 1995, Pages 97-103

  Stokkers, Pieter C F ^a   Camoglio, Luisa ^a   Van Deventer, Sander J H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

animal mode; Crohn's disease; gene polymorphisms; inflammatory bowel disease; tumor necrosis factor

Indexed keywords

TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

ANIMAL MODEL; CONFERENCE PAPER; CROHN DISEASE; DNA POLYMORPHISM; IMMUNOREGULATION; IMMUNOTHERAPY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REMISSION;

ANIMALS; ANTIBODIES; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATORY BOWEL DISEASES; POLYMORPHISM, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029553831     PISSN: 10787852     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (54)

1. Nedwin GE, Naylor SL, Sakaguchi AY, Sakaguchi AY, Smith D, Jarrett-Nedwin J, Pennica D, Goeddel DV, Gray PW: Human tumor necrosis factor genes: Structure, homology and chromosomal localisation. Nucleic Acids Res 13(17):6361-6373, 1985.
2. Nedospasov SA, Shakov AN, Turetskaya RL, Mett VA, Azizov MM, Georgiev GP, Korobko VG, Dobrynin VN, Fillipov SA, Bystrov NS, Boldyreva EF, Chuvpilo SA, Chumakov AM, Shingarova LN, Ovchinnikov YA: Tandem arrangement of the genes coding for human tumour necrosis factor (TNF-a) and lymphotoxin (TNF) in human genome. Cold Spring Harbor Symp Quant Biol 51:611-625, 1986.
3. Spies T, Morton CC, Nedospasov SA, Fiers W, Pious D, Strominger JL: Genes for the tumour necrosis factor a and are linked to the human major histocompatibility complex. Proc Natl Acad Sei USA 83:8699-8702, 1986.
4. Carroll MC, Katzman P, Alicot EM, Koller BH, Geraghty DE, Orr HT, Strominger JL, Spies TS: Linkage map of the human major histocompatibility complex including the tumour necrosis factor genes. Proc Natl Acad Sei USA 84:8535-8539, 1987.
5. Dunham I, Sargent CA, Trowsdale J, Campbell D: Molecular mapping of the human major histocompatibility complex by pulse-field electrophoresis. Proc Natl Acad Sei USA 84:7237-7241, 1987.
6. Udalova IA, Nedospasov SA, Webb GC, Chaplin DD, Turestkaya RL: Highly informative typing of the human TNF locus using six adjacent polymorphic markers. Genomics 16:180-186, 1993.
7. Fugger L, Morling N, Ryder LP, Platz P, Georgsen J, Jakobsen BK, Svejgaard A, Dalhof K, Ranek L: Ncol restriction fragment length polymorphism (RFLP) of the tumor necrosis factor (TNFcc) region in primary biliary sclerosis and in healthy Danes. Scand J Immunol 30:185-189, 1989.
8. Choo SY, Spies T, Strominger JL, Hansen J: Polymorphism in the tumor necrosis factor gene: Association with HLA-B and DR haplotypes. Hum Immunol 23:86, 1988.
9. Badenhoop K, Schwarz G, Trowsdale J, Lewis V, Gale EAM, Botazzo GF: TNF-oc gene polymorphisms in type 1 diabetes mellitus. Diabetologia 32:445-448,1989.
10. Dawkins RL, Leaver A, Cameron PU, Martin E, Kay PH, Christiansen FT: Some disease-associated ancestral haplotypes carry a polymorphism of TNF. Hum Immunol 26:91-97, 1989.
11. Tiwari Jl: "HLA and Disease Associations." Berlin: Springer-Verlag, 1985, pp 32-48.
12. Messer G, Spengler U, Jung MC, Honold G, Blömer K, Pape GR, Riethmüller G, Weiss EH: Polymorphic structure of the tumour necrosis factor (TNF) locus: An Ncol polymorphism in the first intron of the human TNF- gene correlates with a variant amino acid in position 26 and a reduced level of TNF- production. J Exp Med 173:209-219, 1991.
13. Wilson AG, Symons JA, McDowell TL, Di Giovine FS, Duff GW: Effects of tumor necrosis (TNF-a) promoter base transition on transcriptional activity (abstract). Br J Rheumatol 33:89, 1994.
14. Wilson AG, Di Giovine FS, Blakemore AIF, Duff GW: Single base polymorphism in the human tumour necrosis factor alfa (TNF-a) gene detectable by Ncol restriction of PCR product. Hum Mol Genet 1:353, 1992.
15. Wilson AG, De Vries N, Pociot F, Di Giovine FS, Van der Putte LBA, Duff GW: An allelic polymorphism within the tumor necrosis factor a promoter is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 177:557-560, 1993.
16. Freidel AC, Betuel H, Gebuhrer L, Farre A, Lambert J: Cellular and serological subtypes of HLA-DR2. Tissue Antigens 29:129-140, 1987.
17. Toyoda H, Wang SJ, Yang HY, Redfort A, Megalong D, Tyan D, McElree CK, Pressman SR, Shanahan F, Targan SR: Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology 104: 741-748, 1993.
18. Sugimura K, Asakura H, Mizuki M, Inoue M, Hiloi T, Yagita A, Tsuji K, Inoko H: Analysis of genes within the HLA region affecting susceptibility to ulcerative colitis. Hum Immunol 36:112-118, 1993.
19. Masuda H, Nakamura Y, Tanaka T, Hayakawa S: Distinct relationship between HLA-DR genes and intractability of ulcerative colitis. Am J Gastroenterol 89:957-962, 1994.
20. Duerr RH, Neigut DA: Molecularly defined HLA-DR2 alleles in ulcerative colitis and an anti-neutrophil cytoplasmic antibody-positive subgroup. Gastroenterology 108:423-427, 1995.
21. Forcione DG, Sands B, Isselbacher KJ, Rustigi A, Podolski DK, Pillai S: An increased risk of Crohn's disease in individuals who inherit the HLA class II DRB3*0301 allele. Proc Natl Acad Sei USA 93:5094-5098, 1996.
22. Satsangi J, Welsh Kl, Bunce M, Julier C, Farrant JM, Bell Jl, Jewell DP: Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 347:1212-1217, 1996.
23. Wassmuth R, Keller Y, Thompson G, Starck M, Lindhagen T, Holmberg E: HLA DRB1 alleles provide protection against Crohn's disease in Caucasians. Eur J Gastroenterol Hepatol 6:405-411, 1994.
24. Colombel JF, Danze PM, Jacquot S, et al: HLA class II genes and Crohn's disease: Different associations in adults and children. Gastroenterology 108:A800, 1995.
25. Bouma G, Xia B, Crusius BA, Bioque G, Koutroubakis l, Von Blomberg BME, Meuwissen SGM, Pena AS: Distribution of four polymorphisms in the tumor necrosis factor (TNF) genes in patients with inflammatory bowel disease. Clin Exp Immunol 103:391-396, 1996.
26. Bouma G, Crusius JBA, Oudkerk Pool M, Kolkman JJ, Von Blomberg BME, Kostense PJ, Gipharts MJ, Schreuders GMTh, Meuwissen SGM, Pena AS: Secretion of tumour necrosis factor a and lymphotoxin a in relation to polymorphisms in the TNF genes and HLADR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 43:456-463, 1996.
27. Epplen C, Dotzauer B, Jäckel S, Epplen JT, Przuntek H, Pöhlau: Multiple sclerosis (MS): Relation of TNFA promoter and HLA-DRB1 polymorphisms with constitutive TNF secretion (abstract). Eur Cytokine Netw 7(25): 155, 1996.
28. Mayer FR, Messer G, Knabe H, Memepel W, Meurer M, Kolb HJ, Holler E: Polymorphism in the TNF-genes: Association with high inducible TNF-oc levels and severity of aGvHD after allogenic bone marrow transplantation (abstract). Eur Cytokine Netw 7(266):177, 1996.
29. Abraham LJ, Kroeger KM: Effect of the TNFa-308 promoter polymorphism on transcription (abstract). Eur Cytokine Netw 7(183):39, 1996.
30. Brinkman BMN, Huizinga TWJ, Breedveld FC, Verweij CL: Allele-specific quantification of TNFA transcripts in rheumatoid arthritis. Hum Genet 97:813-818, 1996.
31. Brinkman BMN, Zuijdgeest D, Huizinga TWJ, Breedveld FC, Verweij CL: Functional analysis of TNFa alleles by allele-specific transcript quantification and reporter gene studies of TNFa promoter/enhancer sequences (abstract). Eur Cytokine Netw 7(252):149,1996.
32. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W: lnterleukin-10-deficient mice develop chronic enterocolitis. Cell 75:263-274, 1993.
33. Rennick D, Berg D, Kühn R, Müller W: lnterleukin-10 deficient mice. In de Vries J, de Waal Malefyt R (eds): "lnterleukin-10." RG Landes Company, 1995, pp 141-148.
34. hl9h and CD45RB|OW CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J Exp Med 179:589-600, 1994.
35. + T cells. Immunity 1:553-562, 1994.
36. Leach MW, Bean AGO, Mauze S, Coffman RL, Powrie F: Inflammatory bowel disease in C.B-17 seid mice reconstituted with the CD45RB(high) subset of CD(+) T cells. Am J Pathol 146:1503-1515, 1996.
37. Stüber E, Strober W, Neurath M: Blocking the CD40LCD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J Exp Med 183:693-698, 1996.
38. Neurath MF, Fuss I, Kelsall BL, Stüber E, Strober W: Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 182:1281-1290, 1995.
39. Neurath MF, Fuss I, Pasparakis M, Haralambous S, Strober W, Meyer zum Büschenfelde K-H, Kollias G: Predominant role of TNF-a in experimental colitis in mice. Eur Cytokine Netw 7(2):A180, 1996.
40. Derkx B, Taminiau J, Radema S, Stronkhorst A, Wortel C, Tytgat G, van Deventer S: Tumor-necrosis-factor antibody treatment in Crohn's disease. Lancet 342:173174, 1993.
41. Van Dullemen H, van Deventer SJH, Hommes DW, Hannie AB, Jansen J, Tytgat GNJ, Woody J: Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109:129-135, 1995.
42. McCabe RP, Woody J, Van Deventer SJH, Targan SR, Mayer I, Van Hogezand R, Rutgeerts P, Hanauer SB, Podolski D, Eisen CO: A multicenter trial of cA2 anti-tnf chimeric monoclonal antibody in patients with active Crohn's disease. Gastroenterology 110(4):A962, 1996.
43. Targan SR, Rutgeerts P, Hanauer SB, Van Deventer SJH, Mayer L, Present DH, Braakman TAJ, Woody JN: A multicenter trial of anti-tumor necrosis factor (TNF) antibody (CA2) for treatment of patients with active Crohn's disease. Gastroenterology 110(4):A1026, 1996.
44. Cope AP, Londei M, Chu NR, Cohen SB, Eliott MJ, Brennan FM, Maini RN, Feldmann M: Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T-cell receptor/CD3 complex: Reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 94(2):749-760, 1994.
45. Cope AP, Aderka D, Wallach D, Kahan M, Chu NR, Brennan FM, Feldmann M: Soluble TNF receptor production by activated T lymphocytes; differential effects of acute and chronic exposure to TNF. Immunology 84(1):21-30, 1995.
46. Plevy SE, Carramanzana NM, Deem RL, Woody JN, Targan SR: Clinical improvement in Crohn's disease patients treated with anti-TNF-a correlates with downregulated mucosal T helper 1 responses. Gastroenterology 110(4):A993, 1996.
47. Bauditz J, Ruckert Y, Readier A, Nikolaus S, Lochs H, Schreiber S: Tumour necrosis factor inhibition by oxpentifylline and intestinal inflammation in Crohn's disease. Lancet 345(89621:1445, 1995.
48. Nedospasov SA, Udalova IA, Kuprash DV, Turetskaya RL: DNA sequence polymorphism at the human tumor necrosis factor (TNF) locus. J Immunol 147(3):1053-1059, 1991.
49. Jongeneel CV, Briant L, Udalova IA, Sevin A, Nedospasov SA, Cambon-Thomsen A: Extensive genetic polymorphism in the human tumor necrosis factor region and relation to extended HLA haplotypes. Proc Natl Acad Sei USA 88:9717-9721, 1991.
50. Webb GC, Chaplin DD: Genetic variability at the human tumor necrosis factor loci. J Immunol 145:1278-1285, 1990.
51. Partanen J, Koskimies S: Low degree of DNA polymorphisms in the HLA-linked lymphotoxin (tumour necrosis factor ) gene. Scand J Immunol 28:313-316, 1988.
52. Wilson AG, Di Giovine FS, Blakemore AIF, Duff GW: Single base polymorphism in the human tumor necrosis factor alfa (TNF-ot) gene detectable by Ncol restriction of PCR product. Hum Mol Genet 1:353, 1992.
53. D'Alfonso S, Momigliano Richiardi P: A polymorphic variation in a putative regulation box of the TNFA promoter region. Immunogenetics 39:150-154, 1994.
54. Brinkman BMN, Kaijzel EL, Huizinga TWJ, Giphart MJ, Breedveld FC, Verweij CL: Detection of a C-insertion polymorphism within the human tumor necrosis factor alpha (TNFA) gene. Hum Genet 96:493, 1995.